The current standing on the use of denosumab in giant cell tumour of the bone. (16th December 2020)

• Record Type: Journal Article
• Authors: Singh, Vivek Ajit; Puri, Ajay
• Is Part Of: Journal of orthopaedic surgery. Volume 28:Number 3(2020)
• Publication Date: 2020-12-16
• Subjects: bone -- denosumab -- giant cell tumour -- neoadjuvant; Orthopedic surgery -- Periodicals; Orthopedics; Orthopedic surgery; Periodicals; 617.3
• DOI: 10.1177/2309499020979750
• Languages: English
• ISSNs: 1022-5536

Abstract

Giant cell tumour of the bone (GCTB) has been classically treated surgically. With the advent of denosumab, there is potential to use it as a targeted therapy to downstage the tumour and control its progression. Like all new therapies, the dosage, duration, and long-term effects of treatment can only be determined over the time through numerous trials and errors. The current recommendation of use of the monoclonal antibody is 3–4 months of neoadjuvant denosumab in patients with advanced GCTB for cases who were not candidates for primary curettage initially, and prolonged use for surgically unsalvageable GCTB. The use of Denosumab in the adjuvant setting to prevent recurrence is not established.